Accéder au contenu
Merck
  • Foxa1 contributes to the repression of Nanog expression by recruiting Grg3 during the differentiation of pluripotent P19 embryonal carcinoma cells.

Foxa1 contributes to the repression of Nanog expression by recruiting Grg3 during the differentiation of pluripotent P19 embryonal carcinoma cells.

Experimental cell research (2014-05-08)
Tuanhui Chen, Sijia He, Zhen Zhang, Wei Gao, Li Yu, Yongjun Tan
RÉSUMÉ

Transcription factor Foxa1 plays a critical role during neural differentiation and is induced immediately after retinoic acid (RA)-initiated differentiation of pluripotent P19 embryonal carcinoma cells, correlated with the downregulated expression of pluripotency-related genes such as Nanog. To study whether Foxa1 participates in the repression of pluripotency factors, we expressed Foxa1 ectopically in P19 cells and identified that Nanog was repressed directly by Foxa1. We confirmed that Foxa1 was able to interact with Grg3, which is a transcriptional corepressor that expresses in P19 cells as well as during RA-induced P19 cell differentiation. Knockdown of Foxa1 or Grg3 delayed the downregulation of Nanog expression during RA-induced P19 cell differentiation. Furthermore, we found that Foxa1 recruited Grg3 to the Nanog promoter -2kb upstream region and switched the promoter to an inactive chromatin status represented by typical modifications in histone H3. Together, our results suggested a critical involvement of Foxa1 in the negative regulation of Nanog expression during the differentiation of pluripotent stem cells.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Acide rétinoïque, ≥98% (HPLC), powder
Sigma-Aldrich
Sodium hydrogen sulfate, technical grade
USP
Acide rétinoïque, United States Pharmacopeia (USP) Reference Standard
Supelco
Acide rétinoïque, Pharmaceutical Secondary Standard; Certified Reference Material
Acide rétinoïque, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
MISSION® esiRNA, targeting human FOXA1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Foxa1